FINE NEEDLE INJECTION THERAPY DEVICE
20220211953 ยท 2022-07-07
Inventors
- Michael J. Levy (Rochester, MN, US)
- Ferga C. Gleeson (Rochester, MN, US)
- Louis-Michel Wong Kee Song (Rochester, MN, US)
Cpc classification
A61P31/00
HUMAN NECESSITIES
A61M2205/0238
HUMAN NECESSITIES
A61M5/3294
HUMAN NECESSITIES
A61B17/1215
HUMAN NECESSITIES
A61P43/00
HUMAN NECESSITIES
A61M5/427
HUMAN NECESSITIES
A61L24/06
HUMAN NECESSITIES
International classification
A61M5/32
HUMAN NECESSITIES
A61B17/12
HUMAN NECESSITIES
A61L24/06
HUMAN NECESSITIES
Abstract
This document describes methods and materials for improving cancer treatment. For example, this document describes methods and devices for local tumor control and customizable patient treatment.
Claims
1. A method of providing treatment to a patient, the method comprising: delivering a mixture to a targeted area of the patient, the mixture comprising: a therapeutic agent; a glue; and a radiopaque substance.
2. The method of claim 1, wherein the therapeutic agent is at least one of a chemotherapeutic agent, an immunomodulatory agent, or a vaccine.
3. The method of claim 1, wherein the glue is a cyanoacrylate.
4. The method of claim 1, wherein the radiopaque substance is a lipid-based agent.
5. The method of claim 1, wherein the mixture further comprises at least one of a nanoparticle, an alcohol, an anesthetic agent, a radioactive material, a vasoconstricting agent, a vasodilating agent, an ultrasound contrast medium, a ultrasound microbubble, an anti-stromal agent, a pathway inhibitor, an immunotherapy agent, a vaccine, or a combination thereof.
6. The method of claim 1, further comprising providing a needle for delivery of the mixture, wherein the needle defines an inner lumen comprising a coating.
7. The method of claim 6, wherein the coating is at least one of an anticoagulant, a lipid-based agent, an acetone, or a nitromethane.
8. The method of claim 1, further comprising providing a needle for delivery of the mixture, wherein the needle comprising a first lumen and a second lumen.
9. The method of claim 8, further comprising delivering the mixture through the first lumen, and delivering microcoils through the second lumen.
10. A needle assembly for providing treatment to a patient, the needle assembly comprising: a needle housing defining a breakaway region; and a needle enclosed in the needle housing, wherein the breakaway region exposes a portion of the needle.
11. The needle assembly of claim 10, wherein the portion of the needle exposed by the breakaway region has a length to receive wire cutters.
12. The needle assembly of claim 10, wherein when force is applied on either side of the breakaway region, the portion of the needle exposed by the breakaway region breaks.
13. The needle assembly of claim 10, wherein the needle comprises multiple lumens.
14. The needle assembly of claim 10, wherein the needle defines an inner lumen comprising a coating.
15. The needle assembly of claim 14, wherein the coating is at least one of an anticoagulant, a lipid-based agent, an acetone, or a nitromethane.
16. The needle assembly of claim 10, wherein the needle is configured to deliver a mixture to a targeted area of the patient, the mixture comprising: a therapeutic agent; a glue; and a radiopaque substance.
17. The needle assembly of claim 16, wherein the therapeutic agent is a chemotherapeutic agent.
18. The needle assembly of claim 16, wherein the glue is a cyanoacrylate.
19. The needle assembly of claim 16, wherein the radiopaque substance is a lipid-based agent.
20. The needle assembly of claim 16, wherein the mixture further comprises at least one of a nanoparticle, an alcohol, an anesthetic agent, a radioactive material, a vasoconstricting agent, a vasodilating agent, an ultrasound contrast medium, a ultrasound microbubble, an anti-stromal agent, a pathway inhibitor, an immunotherapy agent, a vaccine, or a combination thereof.
Description
DESCRIPTION OF DRAWINGS
[0012]
[0013]
[0014]
[0015] Like reference numbers represent corresponding parts throughout.
DETAILED DESCRIPTION
[0016] This document describes methods and materials for improving cancer treatment. For example, this document describes methods and devices for local tumor control and customizable patient treatment.
[0017] Chemotherapy and radiation therapy have been used to treat pancreatic ductal adenocarcinoma (PDAC). However, the median survival expectancy for locally advanced pancreatic cancer (LAPC) remains at only 9-11 months, even with administration of chemoradiotherapy, and at only 6 months for patients with metastatic disease. Neoadjuvant therapy is routinely administered to patients with LAPC with the aim of tumor downstaging to potentially allow subsequent resection. The limited efficacy of conventional PDAC therapy results from the tumor biology, severe desmoplasia and altered tumor induced biophysical properties that result in neoplastic islands interspersed among dense stroma. This resulting tumor structure topography alters the pattern and limits chemotherapy penetrance to the tumor.
[0018] The devices and methods provided herein can provide new systemic and targeted therapies impacting both tumor cells and the associated microenvironment. In addition, means of precision delivery are provided to improve local tumor control that work in synergy with bespoke individualized therapies to customize patient care and outcome. The local injection can allow delivery of greater drug concentrations and anti-stromal agents, thereby overcoming protective mechanisms developed by neoplastic cells and the microenvironment. By increasing the intratumoral dose of chemotherapy or delivering a targeted agent based on the molecular landscape of the tumor and/or an anti-stromal agent, the therapeutic efficacy can be enhanced, and the risk of adverse events can be reduced.
[0019] Referring to
[0020] Up/down knob 108 can provide actuation of a distal portion (e.g., a bending portion) of endoscope 100 in a first plane. For example, up/down knob 108 can provide actuation in two directions within the first plane. Optionally, up/down knob 108 can provide actuation of the distal portion by mechanical means. For example, up/down knob 108 can provide actuation of the distal portion of the endoscope 100 by rotating a chain and sprocket on a gear that can be attached to angulation wires that extend to the distal portion of the endoscope 100. In some cases, the angulation wires can be attached to rings and pivot pins, such that rotation of the up/down knob 108 causes the distal portion to bend or move in a first direction and/or a second direction within the first plane. In another embodiment, up/down knob 108 can provide actuation of the distal portion by electrical means. For example, the up/down knob 108 can cause actuation of the distal portion via a motor.
[0021] Up/down lock 110 can prevent rotation of the up/down knob 108 when up/down lock 110 is engaged. In some cases, up/down lock 110 can cause previous rotation of the up/down knob 108, and therefore actuation of the distal portion of the endoscope 100, to be locked into place such that the position of the distal portion is maintained. Optionally, when up/down lock 110 is disengaged, up/down knob 108 can be rotated. Alternatively, when up/down lock 110 is disengaged, the position of up/down knob 108 can return to a neutral position (e.g., an original or starting position, such as a position that causes no bending of the distal end of endoscope 100).
[0022] Left/right knob 112 can provide actuation of a distal portion (e.g., a bending portion) of endoscope 100 in a second plane, different from the first plane, for example, in two directions within the second plane. Optionally, left/right knob 112 can provide actuation of the distal portion of the endoscope 100 by rotating a chain and sprocket on a gear that can be attached to angulation wires that extend to the distal portion of the endoscope 100. In some cases, the angulation wires can be attached to rings and pivot pins, such that rotation of the left/right knob 112 causes the distal portion to bend or move in a first direction and/or a second direction within the second plane. Alternatively, left/right knob 112 can provide actuation of the distal portion by electrical means. For example, the left/right knob 112 can cause actuation of the distal portion via a motor.
[0023] Left/right lock 114 can prevent rotation of the left/right knob 112 when left/right lock 114 is engaged. In some cases, left/right lock 114 can cause previous rotation of the left/right knob 112, and therefore actuation of the distal portion of the endoscope 100, to be locked into place such that the position of the distal portion is maintained. In some embodiments, when left/right lock 114 is disengaged, left/right knob 112 can be rotated. Alternatively, when left/right lock 114 is disengaged, the position of left/right knob 112 can return to a neutral position (e.g., an original or starting position, such as a position that causes no bending of the distal end of the endoscope 100).
[0024] First button 116 and/or second button 118 can be valves. For example, first button 116 and/or second button 118 can be a suction valve, an air valve, a water valve, an anti-reflux valve. In some cases, first button 116 and/or second button 118 can include a vent hole. Optionally, first button 116 and/or second button 118 can be remote switches. For example, first button 116 and/or second button 118 can control a light (e.g., turning the light on and/or off), a camera (e.g., turning the camera on and/or off), or a similar device or feature. In some cases, first button 116 and/or second button 118 can be removable, for example, for cleaning. In some cases, first button 116 and/or second button 118 can be electronic switches that can control valves, pumps, or other devices of the endoscope 100. The control valves can interact with various channels of the endoscope 100. Optionally, the control valves can interact with various channels of the endoscope 100 without coming into contact with the fluids (e.g., gases and/or liquids) inside the channels. For example, a mechanical pump can surround the channel and vary a pressure around the channel to cause pumping.
[0025] Cable 120 can be coupled to the other portions of control head 102 of endoscope 100 and can provide means of connection to an external electronic device, such as an endoscopy tower (not shown). The endoscopy tower can include an electronic control valve, such as an air control valve and/or a water control valve. In some cases, the endoscopy tower can include a video image processor that can receive video information from a camera located at a distal end of the endoscope 100. Optionally, the endoscopy tower can provide imaging, such that a user can view images and/or video via the camera. The endoscopy tower can also allow a user to modify parameters of the video or image, such as contrast, brightness, zoom, etc.
[0026] In some cases, body portion 130 can taper, or decrease in diameter as body portion 130 extends away from control head 102. Body portion 130 can provide additional features and/or components of endoscope. For example, body portion 130 can include a valve 140 that can provide access from body portion 130 to a distal end of endoscope 100. In some cases, valve 140 can be positioned at an angle from the body portion 130 such that inserting a tool into valve 140 can be made easier based on the angle between the valve 140 and the body portion 130. Optionally, valve 140 can include a cap, or deflectable valve, such that when a biopsy tool is not being used, valve 140 remains closed to reduce the chance of infection, cross contamination, or spread of other bacteria. In some cases, valve 140 can include means for securing or attaching a tool to valve 140, and accordingly, body portion 130. For example, valve 140 can be a luer lock.
[0027] In some cases, body portion 130 can include a tube 106 (shown in
[0028] Tube 106 can include a distal portion 122. Distal portion 122 can include an ultrasound head 124. Ultrasound head 124 can include a transducer (not shown). In some cases, the transducer can be a linear transducer such that ultrasound images captured are parallel to endoscope 100. In some cases, the transducer can be a radial transducer such that ultrasound images captured are perpendicular to endoscope 100. In some cases, the transducer can be front viewing at the tip (rather than side) of endoscope 100. In some cases, ultrasound head 124 can include a camera such that a user can direct endoscope 100 to a desired location. In some cases, ultrasound head 124 can include a light source to aid in directing endoscope 100 to a desired location. In some cases, ultrasound head 124 can include other devices/features such as apertures, channels, or nozzles.
[0029] As shown in
[0030] In some cases, needle 206 can include a coating along an inner lumen of needle 206. For example, the inner lumen can be coated with an anticoagulant (e.g., to reduce the risk of clot formation), a lipid-based agent or other fatty solvent (e.g., to reduce polymerization of a glue and prevent occlusion of the inner lumen of needle 206 by the glue), a acetone or nitromethane (e.g., to reduce polymerization of a glue and prevent occlusion of the inner lumen of needle 206 by the glue), or a combination thereof.
[0031] In some cases, the instrument channel can be coated with an agent. For example, the instrument channel can be coated with an anticoagulant (e.g., to reduce the risk of clot formation), a lipid-based agent or other fatty solvent (e.g., to reduce polymerization of a glue and prevent occlusion of the instrument channel by the glue), an acetone or nitromethane (e.g., to reduce polymerization of a glue and prevent occlusion of the instrument channel by the glue), or a combination thereof.
[0032] In some cases, needle 206 can include multiple lumens (e.g., two or three lumens). In some cases, multiple lumens can be used such that different agents, in different lumens, are injected at different injection rates. In some cases, multiple lumens can inject different agents at different times, allowing for varying exposure times. In some cases, multiple lumens can be used to deliver a first inactive agent and a second inactive agent separately, such that the combination of the first inactive agent and the second inactive agent causes activation of the agents. In some cases, a final injection of a liquid or physical sealant can be used to prevent retrograde diffusion of the injected agent along the needle track.
[0033] In some cases, multiple lumens can be used to inject microcoils through a first lumen and a liquid agent through a second lumen, eliminating the need to remove needle 206 and insert a second needle. Optionally, the microcoils can be embedded with various agents. For example, the microcoils can be embedded with a glue, a lipid-based agent, a hemostatic agent, a chemotherapeutic agent, a radiosensitive agent, an anti-stromal agent, or a combination thereof.
[0034] In some cases, needle 206 can have an outer diameter that is sufficiently large enough to occupy substantially all the space within the instrument channel. Such a diameter can reduce reflux of blood clots, glue, or other materials which could damage endoscope 100, and can negatively impact imaging. In some cases, needle 206 can have an increased diameter by using an inflatable balloon that can be inflated at a distal portion of the instrument channel. In addition, the inflatable balloon can aid in maintaining needle 206 in a center of the instrument channel, and in a correct plane. In some cases, needle 206 can have an increased diameter by using a thicker outer sheath for needle 206. In some cases, needle 206 can have an increased diameter by using struts.
[0035] In some cases, needle tip 212 can include an inflatable balloon. For example, the inflatable balloon can be inflated once needle tip 212 is advanced into the vessel or duct (e.g., bile duct or pancreatic duct), or fluid collection to help safely hold needle 206 in place. In some cases, the inflatable balloon can be configured such that when inflated, the inflatable balloon overlies needle tip 212, to provide increased safety, for example.
[0036] Breakaway region 208 can provide an exposed region of needle 206. In some cases, breakaway region 208 allows needle 206 to be cut or broken at a proximal end of needle 206, and a proximal end of endoscope 100. In some cases, breakaway region 208 can be sized to allow a wire cutter to reach needle 206, such that needle 206 can be cut. In some cases, breakaway region 208 can be sized to prevent a wire cutter from reaching needle 206. In some cases, needle 206 can be broken by applying force on a proximal region of needle assembly 200 and valve coupling region 202. By cutting or breaking needle 206 at a proximal portion of needle 206, an amount of glue, agents, or other fluids that are retracted into the instrument channel can be reduced, while increasing safety of a user by reducing the risk of a needle stick. For example, needle tip 212 can be retracted into the instrument channel, or into a needle sheath inside the instrument channel, such that needle tip 212 is no longer exposed distal to the instrument channel. Endoscope 100 can be removed from the patient, with needle 206 being removed as well. Once removed, needle 206 can be cut or broken at breakaway region 208, such that distal portion 210 and needle tip 212 can be removed from a distal portion of the instrument channel, while a proximal portion of needle 206 can be removed from valve 140. Such a removal process can reduce an amount of glue, agents, or other fluids from entering, and potentially occluding, the instrument channel. In some cases, breakaway region 208 can also include means for securing needle 206. For example, breakaway region 208 can have an adapter configured to secure needle 206 such that needle tip 212 protrudes from the instrument channel a desired amount, or such that needle tip 212 is securely within the instrument channel.
[0037] While the devices and methods herein have been described with respect to an endoscope, various other modalities may be used to administer therapy. For example, endoscopic ultrasound, standard endoscopy, interventional radiology guided delivery, and via percutaneous routes.
[0038] Further, in some cases, the devices and methods described herein can be used to perform and provide additional treatments. For example, endoscopic ultrasound delivery of an inferior vena cava filter to inhibit clot embolization can be performed. As another example, endoscopic ultrasound delivery of vascular stents can be performed.
Delivery Agent
[0039] In some cases, a delivery agent may be used in conjunction with the needle assembly 200. For example, the therapeutic agent that is being administered to the patient may include a glue and/or a lipid-based agent, or other radiopaque liquid substance. In some cases, the glue is a cyanoacrylate (e.g., Dermabond). In some cases, the therapeutic agent may be a chemotherapeutic. Some advantages of using a glue and/or a radiopaque liquid substance as a delivery agent are as follows. First, the viscosity of the delivery compound delivered can be easily altered to obtain an ideal viscosity. Second, the compound can allow diffusion of the therapeutic agent throughout solid and cystic lesions. Third, imaging modalities (e.g., fluoroscopy, endoscopic ultrasound, etc.) can be used to easily observe a pattern and extent of spread of the therapeutic agent. Fourth, the compound, and therefore the therapeutic agent, can remain within the target site for prolonged periods of time, allowing for increased durability of the treatment. Fifth, a collateral benefit can include vascular compromise with diminished blood flow and cellular death (e.g., of cancerous cells). In some cases, the glue, lipid-based agent, and/or therapeutic agent compound can also be combined with nanoparticles, alcohol, anesthetic agents, radioactive materials, vasoconstriction agents, vasodilating agents, ultrasound contrasts (e.g., to aid with visualization), ultrasound microbubbles (e.g., containing other agents described herein), anti-stromal agents (e.g., to break down fibrosis), targeted therapy based on a molecular signature of the tumor (e.g., mammalian target of rapamycin (mTOR) or poly ADP ribose polymerase (PARP) pathway inhibitors), immunotherapy agents, a vaccine, or a combination thereof. In some cases, an injectant can also serve as a radiopaque, possibly biodegradable, liquid fiducial to facilitate proton and photon radiation therapy.
Target Lesions
[0040] Numerous targets, pathologies, and therapies can benefit from the devices and methods described herein. For example, solid pancreatic tumors may include PDAC, functioning and non-functioning neuroendocrine tumors, lymphoma, second metastasis to the pancreas, etc. There are also several cystic pancreatic tumors (CPT) such as intraductal papillary mucinous neoplasia, mucinous cystic neoplasia, and serous cystadenomas, among others, that would benefit from local therapy. Similarly, many non-pancreatic solid and cystic lesions located within and remote to organs may benefit from local targeted therapy. Targets also include various types of bleeding lesions such as varices (esophageal, gastric, anastomotic, etc.), ulcers (gastroduodenal, etc.), pseudoaneurysms (splenic artery, etc.), etc.
[0041] While this specification contains many specific implementation details, these should not be construed as limitations on the scope of any invention or of what may be claimed, but rather as descriptions of features that may be specific to particular embodiments of particular inventions. Certain features that are described in this specification in the context of separate embodiments can also be implemented in combination in a single embodiment. Conversely, various features that are described in the context of a single embodiment can also be implemented in multiple embodiments separately or in any suitable sub combination. Moreover, although features may be described herein as acting in certain combinations and even initially claimed as such, one or more features from a claimed combination can in some cases be excised from the combination, and the claimed combination may be directed to a sub combination or variation of a sub combination.
[0042] Similarly, while operations are depicted in the drawings in a particular order, this should not be understood as requiring that such operations be performed in the particular order shown or in sequential order, or that all illustrated operations be performed, to achieve desirable results. In certain circumstances, multitasking and parallel processing may be advantageous. Moreover, the separation of various system modules and components in the embodiments described herein should not be understood as requiring such separation in all embodiments, and it should be understood that the described program components and systems can generally be integrated together in a single product or packaged into multiple products.
[0043] Particular embodiments of the subject matter have been described. Other embodiments are within the scope of the following claims. For example, the actions recited in the claims can be performed in a different order and still achieve desirable results. As one example, the process depicted in the accompanying figures does not necessarily require the particular order shown, or sequential order, to achieve desirable results. In certain implementations, multitasking and parallel processing may be advantageous.